Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.

[1]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Schadendorf,et al.  Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  I. Svane,et al.  Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. , 2009, Vaccine.

[4]  A. Hauschild,et al.  Combined treatment with pegylated interferon–α‐2a and dacarbazine in patients with advanced metastatic melanoma , 2008, Cancer.

[5]  A. Hauschild,et al.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.

[6]  A. Hauschild,et al.  Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  C. Tangen,et al.  Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. Rathmell,et al.  Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Kirkwood,et al.  Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials , 2007 .

[10]  C. Garbe,et al.  Diagnosis and treatment of cutaneous melanoma: state of the art 2006. , 2007, Melanoma research.

[11]  R. Dummer,et al.  Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Eggermont,et al.  Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial , 2005, The Lancet.

[13]  M. Marra,et al.  Alpha‐interferon and its effects on signal transduction pathways , 2005, Journal of cellular physiology.

[14]  H. Pehamberger,et al.  Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. , 2004, Journal of Investigative Dermatology.

[15]  C. Garbe,et al.  Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. , 2003, The Lancet. Oncology.

[16]  M. Gore,et al.  Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. , 2003, Cancer treatment reviews.

[17]  M. Gore,et al.  Need for a quantitative meta-analysis of trials of adjuvant interferon in melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Gore,et al.  Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Lens,et al.  Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[21]  N. Cascinelli,et al.  Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial , 2001, The Lancet.

[22]  M. Gore,et al.  Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study , 2001, British Journal of Cancer.

[23]  V. Sondak,et al.  High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Samir K. Gupta,et al.  Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data , 2000 .

[25]  V. Sondak,et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Chastang,et al.  Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases , 1998, The Lancet.

[27]  M. Binder,et al.  Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Garbe.  Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. , 1993, Melanoma research.

[29]  M. Gordon.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2009 .

[30]  M. Gore,et al.  Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Baker.  Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. , 2003, Reviews in gastroenterological disorders.

[32]  Y. Jeong,et al.  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .

[33]  P. Glue,et al.  Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. , 2000, Clinical pharmacology and therapeutics.

[34]  C. Chastang,et al.  Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. , 1998, Lancet.